Pacific Biosciences Of California (PACB) Notes Payables (2017 - 2023)
Pacific Biosciences Of California has reported Notes Payables over the past 8 years, most recently at $500000.0 for Q4 2023.
- For Q4 2023, Notes Payables fell 78.26% year-over-year to $500000.0; the TTM value through Dec 2023 reached $500000.0, down 78.26%, while the annual FY2023 figure was $500000.0, 78.26% down from the prior year.
- Notes Payables for Q4 2023 was $500000.0 at Pacific Biosciences Of California, down from $2.3 million in the prior quarter.
- Over five years, Notes Payables peaked at $15.9 million in Q4 2019 and troughed at $500000.0 in Q4 2023.
- A 4-year average of $9.4 million and a median of $14.9 million in 2019 define the central range for Notes Payables.
- Biggest five-year swings in Notes Payables: surged 43.03% in 2022 and later tumbled 78.26% in 2023.
- Year by year, Notes Payables stood at $15.9 million in 2019, then crashed by 89.87% to $1.6 million in 2021, then skyrocketed by 43.03% to $2.3 million in 2022, then tumbled by 78.26% to $500000.0 in 2023.
- Business Quant data shows Notes Payables for PACB at $500000.0 in Q4 2023, $2.3 million in Q4 2022, and $1.6 million in Q4 2021.